BCX7353 capsules

DRUG2 trials

Sponsors

BioCryst Pharmaceuticals

Conditions

HAEHereditary AngioedemaHereditary Angioedema, HAE

Phase 3

Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE

CompletedNCT03485911

BioCryst PharmaceuticalsHAE, Hereditary Angioedema

Start: 2018-02-06End: 2022-04-06Updated: 2023-06-26

Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan

CompletedNCT03873116

BioCryst PharmaceuticalsHereditary Angioedema, HAE

Start: 2018-12-27End: 2021-07-08Updated: 2024-07-19

Related Papers

Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial.

2024-03-025 citations

Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial.

2023-12-1815 citations

Assessment of HAE prophylaxis transition from androgen therapy to berotralstat: A subset analysis of the APeX-S trial.

2023-11-064 citations

A review of berotralstat for the treatment of hereditary angioedema.

2022-11-294 citations

Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies

Allergy and Asthma Proceedings2021-06-1520 citations

Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study

Clinical and Translational Allergy2021-06-0148 citations

Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2).

2021-04-1537 citations

Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial

Allergy2020-11-2845 citations

Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.

2020-10-21104 citations

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies.

2019-02-0116 citations